FDA approves Zoryve for treatment of seborrheic dermatitis


The FDA has approved Zoryve, a once-daily steroid-free foam, for the treatment of seborrheic dermatitis in individuals aged 9 years and older. This makes Zoryve the first drug approved for this condition with a new mechanism of action in over 20 years. The approval was supported by positive results from the STRATUM phase 3 trial, with 79.5% of patients treated with Zoryve achieving the primary endpoint of IGA success compared with 58% of vehicle-treated patients. Zoryve also showed rapid itch relief and a favorable safety profile for up to 52 weeks of treatment. The drug will be available to wholesalers and dermatology pharmacy channels by the end of January 2024.

Source link

error: Content is protected !!